RecruitingPhase 4NCT06263348

A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

A Multicenter Post-Marketing Observational Study to Evaluate the Long-Term Safety of Dorzagliatin in Patients With Type 2 Diabetes Mellitus

Sponsor

Hua Medicine Limited

Enrollment

2,000 participants

Start Date

Dec 20, 2023

Study Type

INTERVENTIONAL

Conditions

Type2diabetes

Summary

The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This post-marketing safety study monitors the real-world use of dorzagliatin, a newer blood sugar medication, in people with type 2 diabetes. You may be eligible if... - You are 18 or older (male or female) - You have been diagnosed with type 2 diabetes - Your doctor has already prescribed dorzagliatin for you (the prescription must be made before you enroll) - You are willing to participate and sign informed consent You may NOT be eligible if... - You have another type of diabetes (e.g., type 1 diabetes) - Your doctor believes you may be at risk of an allergy or intolerance to dorzagliatin - Your doctor believes you cannot complete the study or are otherwise unsuitable Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDorzagliatin tablets

During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.